Bellini Roberto 4

What Happened

• Roberto Bellini, a director of Inhibikase Therapeutics, was granted 155,000 derivative shares/options on June 26, 2026. The award is reported at $0.00 (no cash paid) on the Form 4; the reported dollar value for the grant itself is $0 (derivative award). This is an equity award (grant), not a purchase or sale.

Key Details

• Transaction date: 2026-06-26; Form 4 filed: 2026-06-30 (timely—filed within the SEC two-business-day rule).
• Transaction type/code: A — Award/Grant (derivative security).
• Amount: 155,000 derivative shares/options; reported price: $0.00; reported value: $0 (as recorded on the Form 4).
• Shares owned after transaction: Not disclosed in the provided filing excerpt.
• Footnote: F1 — "The options will vest on the earlier of June 26, 2027 or the day prior to the next annual meeting of stockholders, subject to the director's continued service through such date."

Context

• This was a grant of derivative awards (likely stock options or restricted stock units) that vest over time; no shares were reported as sold or exercised. Such grants are common as director compensation and do not by themselves indicate buying/selling sentiment. The award will only convert into exercisable/owned shares if/when vesting and any exercise requirements are met.